nodes	percent_of_prediction	percent_of_DWPC	metapath
Oritavancin—Infusion site reaction—Docetaxel—skin cancer	0.0428	0.0428	CcSEcCtD
Oritavancin—Induration—Imiquimod—skin cancer	0.0372	0.0372	CcSEcCtD
Oritavancin—Induration—Bleomycin—skin cancer	0.0264	0.0264	CcSEcCtD
Oritavancin—Aspartate aminotransferase increased—Vismodegib—skin cancer	0.0206	0.0206	CcSEcCtD
Oritavancin—Connective tissue disorder—Vismodegib—skin cancer	0.0156	0.0156	CcSEcCtD
Oritavancin—Malnutrition—Vismodegib—skin cancer	0.0138	0.0138	CcSEcCtD
Oritavancin—Extravasation—Bleomycin—skin cancer	0.0135	0.0135	CcSEcCtD
Oritavancin—Extravasation—Dactinomycin—skin cancer	0.0126	0.0126	CcSEcCtD
Oritavancin—Eosinophilia—Vemurafenib—skin cancer	0.0121	0.0121	CcSEcCtD
Oritavancin—Myalgia—Vismodegib—skin cancer	0.0117	0.0117	CcSEcCtD
Oritavancin—Unspecified disorder of skin and subcutaneous tissue—Vismodegib—skin cancer	0.0117	0.0117	CcSEcCtD
Oritavancin—Wheezing—Bleomycin—skin cancer	0.0115	0.0115	CcSEcCtD
Oritavancin—Nervous system disorder—Vismodegib—skin cancer	0.011	0.011	CcSEcCtD
Oritavancin—Skin disorder—Vismodegib—skin cancer	0.0109	0.0109	CcSEcCtD
Oritavancin—Infestation NOS—Vemurafenib—skin cancer	0.0109	0.0109	CcSEcCtD
Oritavancin—Infestation—Vemurafenib—skin cancer	0.0109	0.0109	CcSEcCtD
Oritavancin—Extravasation—Fluorouracil—skin cancer	0.0105	0.0105	CcSEcCtD
Oritavancin—Musculoskeletal discomfort—Vismodegib—skin cancer	0.0102	0.0102	CcSEcCtD
Oritavancin—Cellulitis—Fluorouracil—skin cancer	0.0101	0.0101	CcSEcCtD
Oritavancin—Gastrointestinal disorder—Vismodegib—skin cancer	0.00971	0.00971	CcSEcCtD
Oritavancin—Oedema peripheral—Vemurafenib—skin cancer	0.00964	0.00964	CcSEcCtD
Oritavancin—Connective tissue disorder—Vemurafenib—skin cancer	0.00961	0.00961	CcSEcCtD
Oritavancin—Infestation NOS—Imiquimod—skin cancer	0.00929	0.00929	CcSEcCtD
Oritavancin—Infestation—Imiquimod—skin cancer	0.00929	0.00929	CcSEcCtD
Oritavancin—Erythema multiforme—Vemurafenib—skin cancer	0.00925	0.00925	CcSEcCtD
Oritavancin—Cardiac disorder—Vemurafenib—skin cancer	0.00908	0.00908	CcSEcCtD
Oritavancin—Mediastinal disorder—Vemurafenib—skin cancer	0.00882	0.00882	CcSEcCtD
Oritavancin—Malnutrition—Vemurafenib—skin cancer	0.00852	0.00852	CcSEcCtD
Oritavancin—Connective tissue disorder—Imiquimod—skin cancer	0.0082	0.0082	CcSEcCtD
Oritavancin—Pruritus—Vismodegib—skin cancer	0.00796	0.00796	CcSEcCtD
Oritavancin—Erythema multiforme—Imiquimod—skin cancer	0.00789	0.00789	CcSEcCtD
Oritavancin—Diarrhoea—Vismodegib—skin cancer	0.0077	0.0077	CcSEcCtD
Oritavancin—Extravasation—Docetaxel—skin cancer	0.00759	0.00759	CcSEcCtD
Oritavancin—Immune system disorder—Imiquimod—skin cancer	0.00754	0.00754	CcSEcCtD
Oritavancin—Mediastinal disorder—Imiquimod—skin cancer	0.00752	0.00752	CcSEcCtD
Oritavancin—Bronchospasm—Bleomycin—skin cancer	0.00728	0.00728	CcSEcCtD
Oritavancin—Malnutrition—Imiquimod—skin cancer	0.00726	0.00726	CcSEcCtD
Oritavancin—Myalgia—Vemurafenib—skin cancer	0.00725	0.00725	CcSEcCtD
Oritavancin—Unspecified disorder of skin and subcutaneous tissue—Vemurafenib—skin cancer	0.0072	0.0072	CcSEcCtD
Oritavancin—Aspartate aminotransferase increased—Dactinomycin—skin cancer	0.00719	0.00719	CcSEcCtD
Oritavancin—Vomiting—Vismodegib—skin cancer	0.00715	0.00715	CcSEcCtD
Oritavancin—Rash—Vismodegib—skin cancer	0.00709	0.00709	CcSEcCtD
Oritavancin—Dermatitis—Vismodegib—skin cancer	0.00709	0.00709	CcSEcCtD
Oritavancin—Blood bilirubin increased—Docetaxel—skin cancer	0.007	0.007	CcSEcCtD
Oritavancin—Infection—Vemurafenib—skin cancer	0.0069	0.0069	CcSEcCtD
Oritavancin—Nervous system disorder—Vemurafenib—skin cancer	0.00682	0.00682	CcSEcCtD
Oritavancin—Skin disorder—Vemurafenib—skin cancer	0.00675	0.00675	CcSEcCtD
Oritavancin—Nausea—Vismodegib—skin cancer	0.00668	0.00668	CcSEcCtD
Oritavancin—Angioedema—Imiquimod—skin cancer	0.00664	0.00664	CcSEcCtD
Oritavancin—Aspartate aminotransferase increased—Temozolomide—skin cancer	0.00651	0.00651	CcSEcCtD
Oritavancin—Alanine aminotransferase increased—Temozolomide—skin cancer	0.00637	0.00637	CcSEcCtD
Oritavancin—Musculoskeletal discomfort—Vemurafenib—skin cancer	0.00633	0.00633	CcSEcCtD
Oritavancin—Myalgia—Imiquimod—skin cancer	0.00618	0.00618	CcSEcCtD
Oritavancin—Unspecified disorder of skin and subcutaneous tissue—Imiquimod—skin cancer	0.00614	0.00614	CcSEcCtD
Oritavancin—Gastrointestinal disorder—Vemurafenib—skin cancer	0.006	0.006	CcSEcCtD
Oritavancin—Infection—Imiquimod—skin cancer	0.00589	0.00589	CcSEcCtD
Oritavancin—Nervous system disorder—Imiquimod—skin cancer	0.00581	0.00581	CcSEcCtD
Oritavancin—Tachycardia—Imiquimod—skin cancer	0.00578	0.00578	CcSEcCtD
Oritavancin—Skin disorder—Imiquimod—skin cancer	0.00576	0.00576	CcSEcCtD
Oritavancin—Eosinophilia—Fluorouracil—skin cancer	0.0057	0.0057	CcSEcCtD
Oritavancin—Infestation NOS—Temozolomide—skin cancer	0.00557	0.00557	CcSEcCtD
Oritavancin—Infestation—Temozolomide—skin cancer	0.00557	0.00557	CcSEcCtD
Oritavancin—Musculoskeletal discomfort—Imiquimod—skin cancer	0.0054	0.0054	CcSEcCtD
Oritavancin—Erythema multiforme—Dactinomycin—skin cancer	0.00523	0.00523	CcSEcCtD
Oritavancin—Infestation—Fluorouracil—skin cancer	0.00513	0.00513	CcSEcCtD
Oritavancin—Infestation NOS—Fluorouracil—skin cancer	0.00513	0.00513	CcSEcCtD
Oritavancin—Hypersensitivity—Vemurafenib—skin cancer	0.00512	0.00512	CcSEcCtD
Oritavancin—Gastrointestinal disorder—Imiquimod—skin cancer	0.00512	0.00512	CcSEcCtD
Oritavancin—Oedema peripheral—Temozolomide—skin cancer	0.00492	0.00492	CcSEcCtD
Oritavancin—Pruritus—Vemurafenib—skin cancer	0.00492	0.00492	CcSEcCtD
Oritavancin—Connective tissue disorder—Temozolomide—skin cancer	0.00491	0.00491	CcSEcCtD
Oritavancin—Anaemia—Bleomycin—skin cancer	0.00477	0.00477	CcSEcCtD
Oritavancin—Diarrhoea—Vemurafenib—skin cancer	0.00476	0.00476	CcSEcCtD
Oritavancin—Erythema multiforme—Temozolomide—skin cancer	0.00473	0.00473	CcSEcCtD
Oritavancin—Urticaria—Imiquimod—skin cancer	0.00471	0.00471	CcSEcCtD
Oritavancin—Cardiac disorder—Temozolomide—skin cancer	0.00464	0.00464	CcSEcCtD
Oritavancin—Dizziness—Vemurafenib—skin cancer	0.0046	0.0046	CcSEcCtD
Oritavancin—Immune system disorder—Temozolomide—skin cancer	0.00452	0.00452	CcSEcCtD
Oritavancin—Mediastinal disorder—Temozolomide—skin cancer	0.00451	0.00451	CcSEcCtD
Oritavancin—Anaemia—Dactinomycin—skin cancer	0.00445	0.00445	CcSEcCtD
Oritavancin—Vomiting—Vemurafenib—skin cancer	0.00442	0.00442	CcSEcCtD
Oritavancin—Myalgia—Bleomycin—skin cancer	0.00439	0.00439	CcSEcCtD
Oritavancin—Rash—Vemurafenib—skin cancer	0.00438	0.00438	CcSEcCtD
Oritavancin—Dermatitis—Vemurafenib—skin cancer	0.00438	0.00438	CcSEcCtD
Oritavancin—Hypersensitivity—Imiquimod—skin cancer	0.00437	0.00437	CcSEcCtD
Oritavancin—Headache—Vemurafenib—skin cancer	0.00435	0.00435	CcSEcCtD
Oritavancin—Malnutrition—Temozolomide—skin cancer	0.00435	0.00435	CcSEcCtD
Oritavancin—Aspartate aminotransferase increased—Docetaxel—skin cancer	0.00433	0.00433	CcSEcCtD
Oritavancin—Alanine aminotransferase increased—Docetaxel—skin cancer	0.00424	0.00424	CcSEcCtD
Oritavancin—Pruritus—Imiquimod—skin cancer	0.00419	0.00419	CcSEcCtD
Oritavancin—Infection—Bleomycin—skin cancer	0.00418	0.00418	CcSEcCtD
Oritavancin—Nausea—Vemurafenib—skin cancer	0.00413	0.00413	CcSEcCtD
Oritavancin—Myalgia—Dactinomycin—skin cancer	0.0041	0.0041	CcSEcCtD
Oritavancin—Bronchospasm—Docetaxel—skin cancer	0.00409	0.00409	CcSEcCtD
Oritavancin—Diarrhoea—Imiquimod—skin cancer	0.00406	0.00406	CcSEcCtD
Oritavancin—Anaemia—Temozolomide—skin cancer	0.00402	0.00402	CcSEcCtD
Oritavancin—Angioedema—Temozolomide—skin cancer	0.00398	0.00398	CcSEcCtD
Oritavancin—Dizziness—Imiquimod—skin cancer	0.00392	0.00392	CcSEcCtD
Oritavancin—Infection—Dactinomycin—skin cancer	0.0039	0.0039	CcSEcCtD
Oritavancin—Musculoskeletal discomfort—Bleomycin—skin cancer	0.00384	0.00384	CcSEcCtD
Oritavancin—Vomiting—Imiquimod—skin cancer	0.00377	0.00377	CcSEcCtD
Oritavancin—Rash—Imiquimod—skin cancer	0.00374	0.00374	CcSEcCtD
Oritavancin—Dermatitis—Imiquimod—skin cancer	0.00373	0.00373	CcSEcCtD
Oritavancin—Headache—Imiquimod—skin cancer	0.00371	0.00371	CcSEcCtD
Oritavancin—Anaemia—Fluorouracil—skin cancer	0.00371	0.00371	CcSEcCtD
Oritavancin—Myalgia—Temozolomide—skin cancer	0.00371	0.00371	CcSEcCtD
Oritavancin—Infestation—Docetaxel—skin cancer	0.0037	0.0037	CcSEcCtD
Oritavancin—Infestation NOS—Docetaxel—skin cancer	0.0037	0.0037	CcSEcCtD
Oritavancin—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—skin cancer	0.00368	0.00368	CcSEcCtD
Oritavancin—Musculoskeletal discomfort—Dactinomycin—skin cancer	0.00358	0.00358	CcSEcCtD
Oritavancin—Infection—Temozolomide—skin cancer	0.00353	0.00353	CcSEcCtD
Oritavancin—Nausea—Imiquimod—skin cancer	0.00352	0.00352	CcSEcCtD
Oritavancin—Nervous system disorder—Temozolomide—skin cancer	0.00348	0.00348	CcSEcCtD
Oritavancin—Skin disorder—Temozolomide—skin cancer	0.00345	0.00345	CcSEcCtD
Oritavancin—Myalgia—Fluorouracil—skin cancer	0.00341	0.00341	CcSEcCtD
Oritavancin—Urticaria—Bleomycin—skin cancer	0.00334	0.00334	CcSEcCtD
Oritavancin—Oedema peripheral—Docetaxel—skin cancer	0.00328	0.00328	CcSEcCtD
Oritavancin—Connective tissue disorder—Docetaxel—skin cancer	0.00327	0.00327	CcSEcCtD
Oritavancin—Infection—Fluorouracil—skin cancer	0.00325	0.00325	CcSEcCtD
Oritavancin—Musculoskeletal discomfort—Temozolomide—skin cancer	0.00324	0.00324	CcSEcCtD
Oritavancin—Nervous system disorder—Fluorouracil—skin cancer	0.00321	0.00321	CcSEcCtD
Oritavancin—Tachycardia—Fluorouracil—skin cancer	0.00319	0.00319	CcSEcCtD
Oritavancin—Erythema multiforme—Docetaxel—skin cancer	0.00314	0.00314	CcSEcCtD
Oritavancin—Hypersensitivity—Bleomycin—skin cancer	0.0031	0.0031	CcSEcCtD
Oritavancin—Cardiac disorder—Docetaxel—skin cancer	0.00309	0.00309	CcSEcCtD
Oritavancin—Gastrointestinal disorder—Temozolomide—skin cancer	0.00307	0.00307	CcSEcCtD
Oritavancin—Immune system disorder—Docetaxel—skin cancer	0.003	0.003	CcSEcCtD
Oritavancin—Mediastinal disorder—Docetaxel—skin cancer	0.003	0.003	CcSEcCtD
Oritavancin—Musculoskeletal discomfort—Fluorouracil—skin cancer	0.00298	0.00298	CcSEcCtD
Oritavancin—Pruritus—Bleomycin—skin cancer	0.00298	0.00298	CcSEcCtD
Oritavancin—Malnutrition—Docetaxel—skin cancer	0.00289	0.00289	CcSEcCtD
Oritavancin—Hypersensitivity—Dactinomycin—skin cancer	0.00289	0.00289	CcSEcCtD
Oritavancin—Gastrointestinal disorder—Fluorouracil—skin cancer	0.00283	0.00283	CcSEcCtD
Oritavancin—Urticaria—Temozolomide—skin cancer	0.00282	0.00282	CcSEcCtD
Oritavancin—Diarrhoea—Dactinomycin—skin cancer	0.00269	0.00269	CcSEcCtD
Oritavancin—Vomiting—Bleomycin—skin cancer	0.00268	0.00268	CcSEcCtD
Oritavancin—Anaemia—Docetaxel—skin cancer	0.00267	0.00267	CcSEcCtD
Oritavancin—Rash—Bleomycin—skin cancer	0.00265	0.00265	CcSEcCtD
Oritavancin—Dermatitis—Bleomycin—skin cancer	0.00265	0.00265	CcSEcCtD
Oritavancin—Hypersensitivity—Temozolomide—skin cancer	0.00262	0.00262	CcSEcCtD
Oritavancin—Urticaria—Fluorouracil—skin cancer	0.0026	0.0026	CcSEcCtD
Oritavancin—Pruritus—Temozolomide—skin cancer	0.00251	0.00251	CcSEcCtD
Oritavancin—Nausea—Bleomycin—skin cancer	0.0025	0.0025	CcSEcCtD
Oritavancin—Vomiting—Dactinomycin—skin cancer	0.0025	0.0025	CcSEcCtD
Oritavancin—Rash—Dactinomycin—skin cancer	0.00248	0.00248	CcSEcCtD
Oritavancin—Myalgia—Docetaxel—skin cancer	0.00246	0.00246	CcSEcCtD
Oritavancin—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—skin cancer	0.00245	0.00245	CcSEcCtD
Oritavancin—Diarrhoea—Temozolomide—skin cancer	0.00243	0.00243	CcSEcCtD
Oritavancin—Hypersensitivity—Fluorouracil—skin cancer	0.00241	0.00241	CcSEcCtD
Oritavancin—Dizziness—Temozolomide—skin cancer	0.00235	0.00235	CcSEcCtD
Oritavancin—Infection—Docetaxel—skin cancer	0.00235	0.00235	CcSEcCtD
Oritavancin—Nausea—Dactinomycin—skin cancer	0.00233	0.00233	CcSEcCtD
Oritavancin—Nervous system disorder—Docetaxel—skin cancer	0.00232	0.00232	CcSEcCtD
Oritavancin—Pruritus—Fluorouracil—skin cancer	0.00232	0.00232	CcSEcCtD
Oritavancin—Tachycardia—Docetaxel—skin cancer	0.00231	0.00231	CcSEcCtD
Oritavancin—Skin disorder—Docetaxel—skin cancer	0.00229	0.00229	CcSEcCtD
Oritavancin—Vomiting—Temozolomide—skin cancer	0.00226	0.00226	CcSEcCtD
Oritavancin—Rash—Temozolomide—skin cancer	0.00224	0.00224	CcSEcCtD
Oritavancin—Diarrhoea—Fluorouracil—skin cancer	0.00224	0.00224	CcSEcCtD
Oritavancin—Dermatitis—Temozolomide—skin cancer	0.00224	0.00224	CcSEcCtD
Oritavancin—Headache—Temozolomide—skin cancer	0.00223	0.00223	CcSEcCtD
Oritavancin—Dizziness—Fluorouracil—skin cancer	0.00216	0.00216	CcSEcCtD
Oritavancin—Musculoskeletal discomfort—Docetaxel—skin cancer	0.00215	0.00215	CcSEcCtD
Oritavancin—Nausea—Temozolomide—skin cancer	0.00211	0.00211	CcSEcCtD
Oritavancin—Vomiting—Fluorouracil—skin cancer	0.00208	0.00208	CcSEcCtD
Oritavancin—Rash—Fluorouracil—skin cancer	0.00206	0.00206	CcSEcCtD
Oritavancin—Dermatitis—Fluorouracil—skin cancer	0.00206	0.00206	CcSEcCtD
Oritavancin—Headache—Fluorouracil—skin cancer	0.00205	0.00205	CcSEcCtD
Oritavancin—Gastrointestinal disorder—Docetaxel—skin cancer	0.00204	0.00204	CcSEcCtD
Oritavancin—Nausea—Fluorouracil—skin cancer	0.00194	0.00194	CcSEcCtD
Oritavancin—Hypersensitivity—Docetaxel—skin cancer	0.00174	0.00174	CcSEcCtD
Oritavancin—Pruritus—Docetaxel—skin cancer	0.00167	0.00167	CcSEcCtD
Oritavancin—Diarrhoea—Docetaxel—skin cancer	0.00162	0.00162	CcSEcCtD
Oritavancin—Dizziness—Docetaxel—skin cancer	0.00156	0.00156	CcSEcCtD
Oritavancin—Vomiting—Docetaxel—skin cancer	0.0015	0.0015	CcSEcCtD
Oritavancin—Rash—Docetaxel—skin cancer	0.00149	0.00149	CcSEcCtD
Oritavancin—Dermatitis—Docetaxel—skin cancer	0.00149	0.00149	CcSEcCtD
Oritavancin—Headache—Docetaxel—skin cancer	0.00148	0.00148	CcSEcCtD
Oritavancin—Nausea—Docetaxel—skin cancer	0.0014	0.0014	CcSEcCtD
